2025 H1 -tulosraportti
110 päivää sitten48 min
Tarjoustasot
First North Denmark
Määrä
Osto
1 683 023
Myynti
Määrä
71 090
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 000 | - | - | ||
| 45 221 | - | - | ||
| 22 000 | - | - | ||
| 39 136 | - | - | ||
| 50 000 | - | - |
Ylin
0,009VWAP
Alin
0,009VaihtoMäärä
0 490 510
VWAP
Ylin
0,009Alin
0,009VaihtoMäärä
0 490 510
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 490 510 | 490 510 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 490 510 | 490 510 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 H1 -tulosraportti | 4.9. | |
| 2024 H2 -tulosraportti | 29.4. | |
| 2024 H1 -tulosraportti | 3.9.2024 | |
| 2023 H2 -tulosraportti | 7.5.2024 | |
| 2023 H1 -tulosraportti | 1.9.2023 |
Datan lähde: Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sittenIf one still can't quite get an overview of what brain+ and Ayla are today, I have made a fact sheet with only data and no noise. 🏛 National and Supranational Health Systems NHS Europe's largest public health system. Defines standards for treatment, evidence, and implementation. Reference for many countries outside the UK. Entry point for national rollout via the ICS structure. If something is accepted here, it is systemically legitimate. World Health Organization Global norm and guideline setter. CST is WHO-recommended. Digital therapeutics with documented effect are prioritized globally. WHO creates global demand – not local pilots. Alzheimer’s Society UK's strongest dementia organization. Professional authority and political voice. Closely linked to NHS, research, and lived experience. Support here = professional endorsement. 🧠 NHS' internal structure NHS Clinical Entrepreneur Programme Selects solutions NHS itself sees scaling potential in. Focus on evidence, implementation, and system fit. NHS says here: “we need to test this one”. Integrated Care Systems 42 regional systems in England. Gathers hospitals, municipalities, care homes, and budgets. This is where rollout decisions are made. Ayla matches the ICS logic: prevention and community care. 🏢 Care sector's power centers Care England The most powerful industry organization for private care homes in the UK. Represents large chains and care groups. Close dialogue with politicians, CQC, and NHS. Access here = access to hundreds of homes. Care Quality Commission Regulator for quality in care homes. Focus on evidence, documentation, medication reduction, and meaningful activity. Ayla directly addresses CQC's criticisms. 🏆 Recognition and legitimacy HSJ Partnership Awards NHS' most prestigious award for partnerships. Shortlisting = national recognition of model and practice, not marketing. UK Dementia Congress National professional platform for dementia. Participation is by invitation. Here the field's common direction is shaped. 🌍 International policy and longevity scenes Longevity Show Gathers WHO, policy, clinical, and system actors. Focus on implementable solutions. Participation signals global relevance. 🇩🇰 Denmark, public welfare systems Danish municipalities: Copenhagen Municipality, Aarhus Municipality, Syddjurs Municipality. Via co-PI, testing, and education. Shows transferability to Nordic welfare systems. 🔗 Overall picture This is not one sector, but an entire ecosystem: Public health system (NHS), regional decision-making structure (ICS), national regulator (CQC), industry organization (Care England), global norm-setter (WHO), national dementia authority (Alzheimer’s Society), international policy scenes, and municipal welfare systems (DK). All are moving in the same direction. 🎯 Conclusion If one still sees Brain+ / Ayla as “a small company hoping for a breakthrough”, one overlooks that they are already working in the right systems, speaking the right language, and being evaluated by the right instances. That is the league where large contracts are formed, often long before the market discovers it.·1 t sitten🧩 Product & regulatory basis Ayla is digital CST (Cognitive Stimulation Therapy) delivered consistently in operation CST is recommended by World Health Organization and NICE Ayla is a CE-marked medical device (Class I) Makes it possible to prepare staff for CST in 1 day Documentation, structure and outcome-tracking built-in 🏛 National and systemic milestones Admitted to NHS Clinical Entrepreneur Programme Works within NHS innovation and evaluation frameworks Matches Integrated Care Systems (ICS) logic: prevention + community care Directly positioned in relation to Care Quality Commission requirements for evidence, documentation and medication reduction 🏢 Industry and sector level Partner with Care England → represents the largest private care groups in UK → direct access to contract volume and ICS dialogue Active in national dementia and care forums Recognized in professional circles, not just investor-oriented communication 🧾 Contracts & customers – UK (by name) Ayla in operation or rollout at, among others: Southcare Homes Group TLC Care Century Care Buckland Care Majesticare Brambles Care Home (Preston) Overall status: 11 care providers ca. 28 care home sites Geographically distributed (Wales, London, Surrey, Midlands) These are recurring contracts across chains – not single pilots. 🇩🇰 Denmark – public collaborations Københavns Kommune Aarhus Kommune Syddjurs Kommune Via: co-pi / development projects staff training municipal testing in practice Shows transferability to Nordic welfare systems. 👩🏫 Workforce & training (scaling) Approx. 90 employees: fully trained CST-facilitators or in active training Training scalable, digital and standardized Removes classic CST bottleneck 🏆 Recognition & legitimacy Shortlisted at HSJ Partnership Awards → NHS’ most prestigious partnership award → Recognition of model and practice, not vision Participation in UK Dementia Congress Visibility on international policy and longevity stages, including Longevity Show 🔁 Customer effect & ROI Fast effects (weeks, not years) Improvements in: cognition communication mood and social contact Less restlessness and lower medication consumption High ROI due to: scalable delivery one facilitator → many citizens low marginal cost 🔗 Overall assessment Brain+ / Ayla now has: finished, regulatorily approved product active contracts in operation named care groups access to the NHS and Care England system trained workforce documented effect national and international legitimacy This is not “birds on the roof”. It is operational presence in the systems where large contracts are formed.- ·1 päivä sittenIt will be fun to follow how many 5 kr sales downwards we can count today, after a lift 😅🧐🧐 good day.
·20 t sittenThought there was an agreement to ignore the price for the rest of 2025 and wait for a green and rising 2026 🤣📈·20 t sitten · MuokattuI actually think it's more about so much else😊 I feel I have a pretty in-depth insight into the case, so I'm really not that affected by it flying a bit up and down during the day. I just can't help but find it peculiar that we so often see trades that are quite high in level, only to be sold down right after by 5 kr. It's not about frustration at all, it's about wonder and a search for logic. There are several things to it. Firstly, fair enough if you just need 5 kr for the bus. Then you'll have to sell off a bit. Next, there's no economic logic in selling at a loss when you've just seen a higher level. And lastly, why exactly after a larger trade that is 10% higher🤷 The only logical explanation must be that some out there get a kick out of being able to manipulate the market by 10% for 5kr.. and here I'm not thinking of anyone in particular 🧐 I just smile and say thank you very much for another fantastic trade 😅😅 the window at this level is getting shorter and shorter day by day.. 
·19.12. · Muokattu"Brain-dead" who is? Mr. Market or The Company ? - 2026 will reveal I guess.... I find it a bit fascinating that kr. 4.600 ( at 09.53 ) can make it fluctuate so much - that's approximately what is spent on Christmas presents on average in North Zealand in 2025.
·19.12.Yes, it seems peculiar. Unfortunately, I didn't manage to buy up a lot more when they were available so cheaply. And one hopes for the best in 2026 if there are a lot of sales.·3 päivää sitten · MuokattuI've just been hit again and again - so I guess it's just a matter of standing up to the headwind - then they'll come to one drop by drop :-) and then the Christmas presents for the family will have to be a bit smaller this year and then maybe they'll get extra big presents in 2026 or none at all :-)- 18.12.·18.12. · MuokattuWhat is The Longevity Show? The Longevity Show is an international top-conference for: healthy aging prevention digital health evidence-based interventions (for both public healthcare systems, private actors, and policy environments) It is not a care home fair and not a startup pitch scene. It is where: systems thinking clinical evidence scalable health meet. The audience is typically: health system leaders policy advisors researchers major healthcare players investors in infrastructure health (not hype) Why is this big for Ayla? 1️⃣ Ayla is positioned in prevention – not care Devika speaks on the Headline Stage about: > “Cognition & Focus: Training the Brain to Age Better” This means: Ayla is positioned before dementia – not just after diagnosis it moves Ayla into longevity / preventative health budgets a much larger market than “dement care” 2️⃣ Ayla is presented as digital therapy The formulation is important: > “a medical device built on Cognitive Stimulation Therapy” It is: treatment evidence scalable system-ready Not “wellness”. Not “care support”. 👉 Therapeutic intervention. 3️⃣ Global scene = global legitimacy The Longevity environment is: USA UK EU Asia Australia It is the same environment that: influences WHO recommendations shapes national prevention strategies shifts money from hospital → community → digital That Ayla is there = Ayla is seen as a global solution, not a local case. One line that summarizes it all Longevity Show moves Ayla from “dementia software” to “global preventative, prescribable brain health therapy”. It’s a much bigger game.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H1 -tulosraportti
110 päivää sitten48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenIf one still can't quite get an overview of what brain+ and Ayla are today, I have made a fact sheet with only data and no noise. 🏛 National and Supranational Health Systems NHS Europe's largest public health system. Defines standards for treatment, evidence, and implementation. Reference for many countries outside the UK. Entry point for national rollout via the ICS structure. If something is accepted here, it is systemically legitimate. World Health Organization Global norm and guideline setter. CST is WHO-recommended. Digital therapeutics with documented effect are prioritized globally. WHO creates global demand – not local pilots. Alzheimer’s Society UK's strongest dementia organization. Professional authority and political voice. Closely linked to NHS, research, and lived experience. Support here = professional endorsement. 🧠 NHS' internal structure NHS Clinical Entrepreneur Programme Selects solutions NHS itself sees scaling potential in. Focus on evidence, implementation, and system fit. NHS says here: “we need to test this one”. Integrated Care Systems 42 regional systems in England. Gathers hospitals, municipalities, care homes, and budgets. This is where rollout decisions are made. Ayla matches the ICS logic: prevention and community care. 🏢 Care sector's power centers Care England The most powerful industry organization for private care homes in the UK. Represents large chains and care groups. Close dialogue with politicians, CQC, and NHS. Access here = access to hundreds of homes. Care Quality Commission Regulator for quality in care homes. Focus on evidence, documentation, medication reduction, and meaningful activity. Ayla directly addresses CQC's criticisms. 🏆 Recognition and legitimacy HSJ Partnership Awards NHS' most prestigious award for partnerships. Shortlisting = national recognition of model and practice, not marketing. UK Dementia Congress National professional platform for dementia. Participation is by invitation. Here the field's common direction is shaped. 🌍 International policy and longevity scenes Longevity Show Gathers WHO, policy, clinical, and system actors. Focus on implementable solutions. Participation signals global relevance. 🇩🇰 Denmark, public welfare systems Danish municipalities: Copenhagen Municipality, Aarhus Municipality, Syddjurs Municipality. Via co-PI, testing, and education. Shows transferability to Nordic welfare systems. 🔗 Overall picture This is not one sector, but an entire ecosystem: Public health system (NHS), regional decision-making structure (ICS), national regulator (CQC), industry organization (Care England), global norm-setter (WHO), national dementia authority (Alzheimer’s Society), international policy scenes, and municipal welfare systems (DK). All are moving in the same direction. 🎯 Conclusion If one still sees Brain+ / Ayla as “a small company hoping for a breakthrough”, one overlooks that they are already working in the right systems, speaking the right language, and being evaluated by the right instances. That is the league where large contracts are formed, often long before the market discovers it.·1 t sitten🧩 Product & regulatory basis Ayla is digital CST (Cognitive Stimulation Therapy) delivered consistently in operation CST is recommended by World Health Organization and NICE Ayla is a CE-marked medical device (Class I) Makes it possible to prepare staff for CST in 1 day Documentation, structure and outcome-tracking built-in 🏛 National and systemic milestones Admitted to NHS Clinical Entrepreneur Programme Works within NHS innovation and evaluation frameworks Matches Integrated Care Systems (ICS) logic: prevention + community care Directly positioned in relation to Care Quality Commission requirements for evidence, documentation and medication reduction 🏢 Industry and sector level Partner with Care England → represents the largest private care groups in UK → direct access to contract volume and ICS dialogue Active in national dementia and care forums Recognized in professional circles, not just investor-oriented communication 🧾 Contracts & customers – UK (by name) Ayla in operation or rollout at, among others: Southcare Homes Group TLC Care Century Care Buckland Care Majesticare Brambles Care Home (Preston) Overall status: 11 care providers ca. 28 care home sites Geographically distributed (Wales, London, Surrey, Midlands) These are recurring contracts across chains – not single pilots. 🇩🇰 Denmark – public collaborations Københavns Kommune Aarhus Kommune Syddjurs Kommune Via: co-pi / development projects staff training municipal testing in practice Shows transferability to Nordic welfare systems. 👩🏫 Workforce & training (scaling) Approx. 90 employees: fully trained CST-facilitators or in active training Training scalable, digital and standardized Removes classic CST bottleneck 🏆 Recognition & legitimacy Shortlisted at HSJ Partnership Awards → NHS’ most prestigious partnership award → Recognition of model and practice, not vision Participation in UK Dementia Congress Visibility on international policy and longevity stages, including Longevity Show 🔁 Customer effect & ROI Fast effects (weeks, not years) Improvements in: cognition communication mood and social contact Less restlessness and lower medication consumption High ROI due to: scalable delivery one facilitator → many citizens low marginal cost 🔗 Overall assessment Brain+ / Ayla now has: finished, regulatorily approved product active contracts in operation named care groups access to the NHS and Care England system trained workforce documented effect national and international legitimacy This is not “birds on the roof”. It is operational presence in the systems where large contracts are formed.
- ·1 päivä sittenIt will be fun to follow how many 5 kr sales downwards we can count today, after a lift 😅🧐🧐 good day.·20 t sittenThought there was an agreement to ignore the price for the rest of 2025 and wait for a green and rising 2026 🤣📈·20 t sitten · MuokattuI actually think it's more about so much else😊 I feel I have a pretty in-depth insight into the case, so I'm really not that affected by it flying a bit up and down during the day. I just can't help but find it peculiar that we so often see trades that are quite high in level, only to be sold down right after by 5 kr. It's not about frustration at all, it's about wonder and a search for logic. There are several things to it. Firstly, fair enough if you just need 5 kr for the bus. Then you'll have to sell off a bit. Next, there's no economic logic in selling at a loss when you've just seen a higher level. And lastly, why exactly after a larger trade that is 10% higher🤷 The only logical explanation must be that some out there get a kick out of being able to manipulate the market by 10% for 5kr.. and here I'm not thinking of anyone in particular 🧐 I just smile and say thank you very much for another fantastic trade 😅😅 the window at this level is getting shorter and shorter day by day..
- ·19.12. · Muokattu"Brain-dead" who is? Mr. Market or The Company ? - 2026 will reveal I guess.... I find it a bit fascinating that kr. 4.600 ( at 09.53 ) can make it fluctuate so much - that's approximately what is spent on Christmas presents on average in North Zealand in 2025.·19.12.Yes, it seems peculiar. Unfortunately, I didn't manage to buy up a lot more when they were available so cheaply. And one hopes for the best in 2026 if there are a lot of sales.·3 päivää sitten · MuokattuI've just been hit again and again - so I guess it's just a matter of standing up to the headwind - then they'll come to one drop by drop :-) and then the Christmas presents for the family will have to be a bit smaller this year and then maybe they'll get extra big presents in 2026 or none at all :-)
- 18.12.·18.12. · MuokattuWhat is The Longevity Show? The Longevity Show is an international top-conference for: healthy aging prevention digital health evidence-based interventions (for both public healthcare systems, private actors, and policy environments) It is not a care home fair and not a startup pitch scene. It is where: systems thinking clinical evidence scalable health meet. The audience is typically: health system leaders policy advisors researchers major healthcare players investors in infrastructure health (not hype) Why is this big for Ayla? 1️⃣ Ayla is positioned in prevention – not care Devika speaks on the Headline Stage about: > “Cognition & Focus: Training the Brain to Age Better” This means: Ayla is positioned before dementia – not just after diagnosis it moves Ayla into longevity / preventative health budgets a much larger market than “dement care” 2️⃣ Ayla is presented as digital therapy The formulation is important: > “a medical device built on Cognitive Stimulation Therapy” It is: treatment evidence scalable system-ready Not “wellness”. Not “care support”. 👉 Therapeutic intervention. 3️⃣ Global scene = global legitimacy The Longevity environment is: USA UK EU Asia Australia It is the same environment that: influences WHO recommendations shapes national prevention strategies shifts money from hospital → community → digital That Ayla is there = Ayla is seen as a global solution, not a local case. One line that summarizes it all Longevity Show moves Ayla from “dementia software” to “global preventative, prescribable brain health therapy”. It’s a much bigger game.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
1 683 023
Myynti
Määrä
71 090
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 000 | - | - | ||
| 45 221 | - | - | ||
| 22 000 | - | - | ||
| 39 136 | - | - | ||
| 50 000 | - | - |
Ylin
0,009VWAP
Alin
0,009VaihtoMäärä
0 490 510
VWAP
Ylin
0,009Alin
0,009VaihtoMäärä
0 490 510
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 490 510 | 490 510 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 490 510 | 490 510 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 H1 -tulosraportti | 4.9. | |
| 2024 H2 -tulosraportti | 29.4. | |
| 2024 H1 -tulosraportti | 3.9.2024 | |
| 2023 H2 -tulosraportti | 7.5.2024 | |
| 2023 H1 -tulosraportti | 1.9.2023 |
Datan lähde: Quartr
2025 H1 -tulosraportti
110 päivää sitten48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 H1 -tulosraportti | 4.9. | |
| 2024 H2 -tulosraportti | 29.4. | |
| 2024 H1 -tulosraportti | 3.9.2024 | |
| 2023 H2 -tulosraportti | 7.5.2024 | |
| 2023 H1 -tulosraportti | 1.9.2023 |
Datan lähde: Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenIf one still can't quite get an overview of what brain+ and Ayla are today, I have made a fact sheet with only data and no noise. 🏛 National and Supranational Health Systems NHS Europe's largest public health system. Defines standards for treatment, evidence, and implementation. Reference for many countries outside the UK. Entry point for national rollout via the ICS structure. If something is accepted here, it is systemically legitimate. World Health Organization Global norm and guideline setter. CST is WHO-recommended. Digital therapeutics with documented effect are prioritized globally. WHO creates global demand – not local pilots. Alzheimer’s Society UK's strongest dementia organization. Professional authority and political voice. Closely linked to NHS, research, and lived experience. Support here = professional endorsement. 🧠 NHS' internal structure NHS Clinical Entrepreneur Programme Selects solutions NHS itself sees scaling potential in. Focus on evidence, implementation, and system fit. NHS says here: “we need to test this one”. Integrated Care Systems 42 regional systems in England. Gathers hospitals, municipalities, care homes, and budgets. This is where rollout decisions are made. Ayla matches the ICS logic: prevention and community care. 🏢 Care sector's power centers Care England The most powerful industry organization for private care homes in the UK. Represents large chains and care groups. Close dialogue with politicians, CQC, and NHS. Access here = access to hundreds of homes. Care Quality Commission Regulator for quality in care homes. Focus on evidence, documentation, medication reduction, and meaningful activity. Ayla directly addresses CQC's criticisms. 🏆 Recognition and legitimacy HSJ Partnership Awards NHS' most prestigious award for partnerships. Shortlisting = national recognition of model and practice, not marketing. UK Dementia Congress National professional platform for dementia. Participation is by invitation. Here the field's common direction is shaped. 🌍 International policy and longevity scenes Longevity Show Gathers WHO, policy, clinical, and system actors. Focus on implementable solutions. Participation signals global relevance. 🇩🇰 Denmark, public welfare systems Danish municipalities: Copenhagen Municipality, Aarhus Municipality, Syddjurs Municipality. Via co-PI, testing, and education. Shows transferability to Nordic welfare systems. 🔗 Overall picture This is not one sector, but an entire ecosystem: Public health system (NHS), regional decision-making structure (ICS), national regulator (CQC), industry organization (Care England), global norm-setter (WHO), national dementia authority (Alzheimer’s Society), international policy scenes, and municipal welfare systems (DK). All are moving in the same direction. 🎯 Conclusion If one still sees Brain+ / Ayla as “a small company hoping for a breakthrough”, one overlooks that they are already working in the right systems, speaking the right language, and being evaluated by the right instances. That is the league where large contracts are formed, often long before the market discovers it.·1 t sitten🧩 Product & regulatory basis Ayla is digital CST (Cognitive Stimulation Therapy) delivered consistently in operation CST is recommended by World Health Organization and NICE Ayla is a CE-marked medical device (Class I) Makes it possible to prepare staff for CST in 1 day Documentation, structure and outcome-tracking built-in 🏛 National and systemic milestones Admitted to NHS Clinical Entrepreneur Programme Works within NHS innovation and evaluation frameworks Matches Integrated Care Systems (ICS) logic: prevention + community care Directly positioned in relation to Care Quality Commission requirements for evidence, documentation and medication reduction 🏢 Industry and sector level Partner with Care England → represents the largest private care groups in UK → direct access to contract volume and ICS dialogue Active in national dementia and care forums Recognized in professional circles, not just investor-oriented communication 🧾 Contracts & customers – UK (by name) Ayla in operation or rollout at, among others: Southcare Homes Group TLC Care Century Care Buckland Care Majesticare Brambles Care Home (Preston) Overall status: 11 care providers ca. 28 care home sites Geographically distributed (Wales, London, Surrey, Midlands) These are recurring contracts across chains – not single pilots. 🇩🇰 Denmark – public collaborations Københavns Kommune Aarhus Kommune Syddjurs Kommune Via: co-pi / development projects staff training municipal testing in practice Shows transferability to Nordic welfare systems. 👩🏫 Workforce & training (scaling) Approx. 90 employees: fully trained CST-facilitators or in active training Training scalable, digital and standardized Removes classic CST bottleneck 🏆 Recognition & legitimacy Shortlisted at HSJ Partnership Awards → NHS’ most prestigious partnership award → Recognition of model and practice, not vision Participation in UK Dementia Congress Visibility on international policy and longevity stages, including Longevity Show 🔁 Customer effect & ROI Fast effects (weeks, not years) Improvements in: cognition communication mood and social contact Less restlessness and lower medication consumption High ROI due to: scalable delivery one facilitator → many citizens low marginal cost 🔗 Overall assessment Brain+ / Ayla now has: finished, regulatorily approved product active contracts in operation named care groups access to the NHS and Care England system trained workforce documented effect national and international legitimacy This is not “birds on the roof”. It is operational presence in the systems where large contracts are formed.
- ·1 päivä sittenIt will be fun to follow how many 5 kr sales downwards we can count today, after a lift 😅🧐🧐 good day.·20 t sittenThought there was an agreement to ignore the price for the rest of 2025 and wait for a green and rising 2026 🤣📈·20 t sitten · MuokattuI actually think it's more about so much else😊 I feel I have a pretty in-depth insight into the case, so I'm really not that affected by it flying a bit up and down during the day. I just can't help but find it peculiar that we so often see trades that are quite high in level, only to be sold down right after by 5 kr. It's not about frustration at all, it's about wonder and a search for logic. There are several things to it. Firstly, fair enough if you just need 5 kr for the bus. Then you'll have to sell off a bit. Next, there's no economic logic in selling at a loss when you've just seen a higher level. And lastly, why exactly after a larger trade that is 10% higher🤷 The only logical explanation must be that some out there get a kick out of being able to manipulate the market by 10% for 5kr.. and here I'm not thinking of anyone in particular 🧐 I just smile and say thank you very much for another fantastic trade 😅😅 the window at this level is getting shorter and shorter day by day..
- ·19.12. · Muokattu"Brain-dead" who is? Mr. Market or The Company ? - 2026 will reveal I guess.... I find it a bit fascinating that kr. 4.600 ( at 09.53 ) can make it fluctuate so much - that's approximately what is spent on Christmas presents on average in North Zealand in 2025.·19.12.Yes, it seems peculiar. Unfortunately, I didn't manage to buy up a lot more when they were available so cheaply. And one hopes for the best in 2026 if there are a lot of sales.·3 päivää sitten · MuokattuI've just been hit again and again - so I guess it's just a matter of standing up to the headwind - then they'll come to one drop by drop :-) and then the Christmas presents for the family will have to be a bit smaller this year and then maybe they'll get extra big presents in 2026 or none at all :-)
- 18.12.·18.12. · MuokattuWhat is The Longevity Show? The Longevity Show is an international top-conference for: healthy aging prevention digital health evidence-based interventions (for both public healthcare systems, private actors, and policy environments) It is not a care home fair and not a startup pitch scene. It is where: systems thinking clinical evidence scalable health meet. The audience is typically: health system leaders policy advisors researchers major healthcare players investors in infrastructure health (not hype) Why is this big for Ayla? 1️⃣ Ayla is positioned in prevention – not care Devika speaks on the Headline Stage about: > “Cognition & Focus: Training the Brain to Age Better” This means: Ayla is positioned before dementia – not just after diagnosis it moves Ayla into longevity / preventative health budgets a much larger market than “dement care” 2️⃣ Ayla is presented as digital therapy The formulation is important: > “a medical device built on Cognitive Stimulation Therapy” It is: treatment evidence scalable system-ready Not “wellness”. Not “care support”. 👉 Therapeutic intervention. 3️⃣ Global scene = global legitimacy The Longevity environment is: USA UK EU Asia Australia It is the same environment that: influences WHO recommendations shapes national prevention strategies shifts money from hospital → community → digital That Ayla is there = Ayla is seen as a global solution, not a local case. One line that summarizes it all Longevity Show moves Ayla from “dementia software” to “global preventative, prescribable brain health therapy”. It’s a much bigger game.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
1 683 023
Myynti
Määrä
71 090
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 000 | - | - | ||
| 45 221 | - | - | ||
| 22 000 | - | - | ||
| 39 136 | - | - | ||
| 50 000 | - | - |
Ylin
0,009VWAP
Alin
0,009VaihtoMäärä
0 490 510
VWAP
Ylin
0,009Alin
0,009VaihtoMäärä
0 490 510
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 490 510 | 490 510 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 490 510 | 490 510 | 0 | 0 |